Welcome to our dedicated page for Lobe Sciences news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences stock.
Lobe Sciences Ltd. (OTCQB: LOBEF) generates news primarily as a clinical-stage biopharmaceutical company advancing therapies for diseases with significant unmet medical needs. The company’s disclosures highlight programs in rare neurological and hematological conditions, including chronic cluster headache and sickle cell disease, advanced through its subsidiaries Cynaptec Pharmaceuticals, Inc. and Altemia, Inc.
News updates for Lobe Sciences often cover developments in its lead CNS therapeutic candidate L-130 (also referred to as Conjugated Psilocin™ or psilocin mucate), which is being developed by majority-owned Cynaptec for chronic cluster headache and potential additional CNS indications under strategic review. Announcements have described completion of a Phase 1a study in healthy volunteers, ongoing work aligned with U.S. FDA Pre-IND guidance, and financing transactions at the subsidiary level intended to support further development.
Investors and followers of LOBEF can also expect coverage of Altemia, Inc.’s work on S-100, an early-stage therapeutic candidate for sickle cell disease, and a proprietary medical food in early-stage distribution aimed at addressing nutritional deficiencies commonly observed in patients with sickle cell disease. Company news has discussed how Lobe prioritizes S-100 within its sickle cell program and maintains limited commercialization efforts while assessing reimbursement pathways.
Lobe Sciences’ news flow additionally includes corporate and capital markets updates, such as private placements, debt settlements through equity issuance, leadership transition, Board renewal, and the appointment of new directors with experience in corporate governance, securities law, and international pharmaceutical business development. The company also reports on participation in industry conferences and patient-focused events related to cluster headache and other underserved conditions. Readers interested in LOBEF can use this news page to follow the company’s clinical progress, financing activities, governance developments, and strategic initiatives as disclosed in its official releases.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) has announced the creation of a wholly owned U.S. subsidiary, Alera Pharma, Inc. This new entity will focus on neurology and be assigned the intellectual property rights for Lobe's lead compound, Psilocin Mucate. Key appointments include:
- Rick Goulburn as CEO of Alera Pharma
- Dr. Frederick D. Sancilio as Chairman of Alera Pharma's Board
- Dr. Harry Jacobson, Wesley Ramjeet, and Rick Goulburn as Board Members
- Ilan Hayman joining Alera's executive management team
Lobe Sciences Australia Pty will become a subsidiary of Alera Pharma. The company also received a Notice of Allowance from the US PTO for its Patent Application Serial No. 18/411,576. This restructuring aims to simplify Lobe Sciences' operations into three entities: Lobe Sciences , Alera Pharma, and Altemia,
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), a biopharmaceutical company, has announced significant changes to its leadership structure. At the company's annual general meeting, shareholders elected a new Board of Directors comprising Dr. Frederick D. Sancilio, Dr. Harry Jacobson, and Mr. Wesley Ramjeet. Following this, the Board appointed Dr. Sancilio as Chairman and CEO, replacing the departing CEO Philip Young and COO Baxter Phillips III.
The Board also expanded with the addition of Mr. Rick Goulburn as its fourth member, expected to take on a leadership role in pursuing the company's strategic goals. Additionally, Mr. Jeremy Wright joined as a Board and Executive Advisor to provide guidance on strategic and administrative matters. These changes mark a significant shift in Lobe Sciences' leadership as it continues its focus on developing medicines for diseases with unmet medical needs.
Lobe Sciences, a biopharmaceutical company (OTCQB: LOBEF), announced its strategic efforts to enhance shareholder value, including up-listing to the Australian Securities Exchange or the New York Stock Exchange.
The company secured a $500,000 convertible note to improve its balance sheet, reducing short-term debt and preparing for long-term funding. The note is provided by Clearway Global, , and Quality Chemical Laboratories, Inc.
Lobe also plans to out-license its proprietary assets, especially L-130 and Altemia, and aims to communicate its significant scientific achievements through a series of market updates. The Annual General Meeting is scheduled for 22 July 2024.
Lobe Sciences (OTCQB: LOBEF, CSE: LOBE), a biopharmaceutical firm specializing in transformative medicines for rare diseases, has appointed Wesley Ramjeet to its Board of Directors. Ramjeet, CEO and Founder of PPMT Strategic Group, brings over two decades of strategic financial expertise, with notable achievements in acquisitions, IPOs, and growth initiatives across various industries. His leadership has driven significant growth and successful exits, including a 30x increase for MD Logic Wellness and a notable turnaround for a medical device company. CEO Philip J Young highlighted Ramjeet's strategic insights as key for Lobe's mission to advance innovative treatments for neurological disorders.
Ramjeet has also made significant contributions to the nonprofit sector, including founding Lions Unleashed and serving on the Board of Trustees for the Universal Hip Hop Museum. He is a CPA and holds a degree in Accounting from St. John’s University.
Lobe Sciences announced that Frederick D. Sancilio Ph.D. is joining its Board of Directors. Dr. Sancilio brings over 40 years of experience in pharmaceutical sciences, founding multiple successful companies, including aaiPharma. His expertise is expected to boost Lobe's efforts in developing treatments for rare diseases and mental health conditions. The company aims to leverage his experience to advance its L-130 oral psilocin program and expand the reach of Altemia, a medical food for Sickle Cell Disease. Dr. Sancilio's previous roles include significant contributions to drug development and FDA approvals.
Lobe Sciences announced that Dr. Harry Jacobson, a former director at Merck and Vanderbilt Vice-Chancellor, will join its Board of Directors. Dr. Jacobson boasts over three decades of experience in healthcare, biotechnology, and medical innovation. His background includes roles such as Vice Chancellor for Health Affairs at Vanderbilt University Medical Center, where he expanded the budget from $750M to $2.5B. He has also founded and co-founded multiple companies, including Renal Care Group and Contact Software, and has served on the boards of Merck, Kinetic Concepts, and Renal Care Group. Dr. Jacobson’s addition is expected to drive Lobe’s development and commercialization of treatments for Chronic Cluster Headaches and Sickle Cell Disease.
Lobe Sciences (OTCQB: LOBEF) and Clearway Global have announced a change of control, with Clearway gaining voting control of Lobe.
This follows Lobe's acquisition of Altemia & Company, resulting in Clearway owning 52.69% of Lobe's shares. The companies aim to enhance growth strategies, including appointing new board members, securing funding, and addressing accounts payable.
Lobe has issued 16,424,220 shares to Clearway under a consulting agreement. The focus will be on Lobe’s L-130, an oral Psilocin-based drug, with plans for an investor communications program to share recent trial data and unlock shareholder value. The Annual General Meeting is scheduled for July 22, 2024.
FAQ
What is the current stock price of Lobe Sciences (LOBEF)?
What is the market cap of Lobe Sciences (LOBEF)?
